[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-microvascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-microvascular-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,40,70,94,127,147,170,196,219,243,267,290,314,336],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100592276","self-expanding-coronary-sinus-reducer-for-treatment-of-symptomatic-coronary-microvascular-dysfunction-cmd-serra-i-study-100592276",false,"NCT06991322","Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)","Inclusion Criteria:\n\n1. Older than 18 years of age.\n2. Left ventricular ejection fraction (LVEF) is greater than or equal to 25% within the 12 months before the index procedure.\n3. Greater than or equal to 30 days of persistent symptomatic coronary microvascular dysfunction (angina pectoris, or equivalent symptoms) (classified as CCS Grade II-IV angina, or NYHA Class 2 or 3 equivalent non-anginal functional impairment) despite optimal medical therapy as determined by Investigator and confirmed by the Central Screening Committee.\n4. CFR\\\u003C2.5 measured with continuous thermodilution within 30 days of index procedure.\n5. Sustained angina (or equivalent symptoms) reported for at least 2 weeks leading up to the index procedure, as reported via the ORBITA-app.\n6. Willing and able to sign informed consent.\n7. Willing to comply with the specified follow-up evaluations.\n8. Mean right atrial pressure ≤15 mmHg.\n9. The CS anatomy is suitable for implantation at the Investigator's discretion.\n\nExclusion Criteria:\n\n1. Significant obstructive epicardial disease (greater than 50% diameter stenosis) that can be treated with PCI or CABG as determined by Investigator and confirmed by the Central Screening Committee.\n2. Recent (less than 30 days before index procedure) troponin or CKMB positive acute coronary syndrome (NSTEMI or STEMI) with evidence of ischemia.\n3. Extra-coronary contributory causes of angina - e.g., untreated hyperthyroidism, anemia (Hgb less than 9 g\u002FdL), uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg despite medications), atrial fibrillation with a rapid ventricular response (consistently greater than 100 bpm despite medications) or other tachyarrhythmia, severe aortic stenosis, decompensated heart failure, hypertrophic cardiomyopathy with left ventricular outflow tract obstruction or asymmetric septal hypertrophy (concentric left ventricular hypertrophy is not an exclusion criterion).\n4. NYHA class IV or decompensated HF or hospitalization due to HF during the 90 days before the index procedure.\n5. Life-threatening rhythm disorders or any rhythm disorders that would require cardiac resynchronization therapy or lead placement in the coronary sinus.\n6. Severe chronic obstructive pulmonary disease (COPD) as indicated by a forced expiratory volume in one second (FEV1) of less than 1.0L or need for home daytime oxygen or regular oral steroids.\n7. Severe valvular heart disease (any valve).\n8. Moderate (TAPSE\\\u003C12) or severe RV dysfunction (TAPSE\\\u003C8) by echocardiography.\n9. A pacemaker electrode\u002Flead is present in the coronary sinus.\n10. Recent implantation of a new pacemaker or defibrillator leads with any electrode in the right atrium within 90 days of the index procedure.\n11. Chronic severe renal failure (estimated eGFR less than 30 mL\u002Fmin\u002F1.73m2 or equivalent) or subjects on chronic dialysis.\n12. Known allergy to titanium, nickel, platinum, tungsten or known inability to tolerate contrast medium.\n13. Any clinical condition that might interfere with the trial protocol or the subject's ability to be compliant with the trial protocol (e.g., active alcohol or illicit substance use, cognitive decline).\n14. Currently enrolled in another investigational device or drug trial that has not reached its primary endpoint or might clinically interfere with the current trial endpoints or procedures.\n15. Pregnant or planning pregnancy within the next 12 months (females of reproductive potential must have a negative pregnancy test within 7 days of the procedure).\n16. Part of a vulnerable population who, in the investigator's judgment, cannot give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances, or lack of autonomy.\n17. Inability to tolerate dual antiplatelet therapy for 6 months if not on a chronic oral anticoagulant, or inability to tolerate a P2Y12 inhibitor for at least 6 months if on a chronic oral anticoagulant.\n18. Comorbidities limiting life expectancy to less than one year.\n19. Currently hospitalized for definite or suspected COVID-19.","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"NA","VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.",[25,26],"Coronary Microvascular Dysfunction","Coronary Microvascular Disease","RECRUITING","2026-05-14",{"date":30,"type":31},"2026-05-15","ACTUAL",{"date":33,"type":31},"2025-06-18",{"date":35,"type":19},"2027-04",{"name":37,"class":38},"VahatiCor, Inc.","INDUSTRY",3,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100503894","coronary-flow-during-rapid-heart-rates-100503894","NCT05841199","Coronary Flow During Rapid Heart Rates","Coronary Epicardial and Microcirculatory Determinants of Ventricular Tachycardia Tolerability","VT flow","Inclusion Criteria:\n\n* Able to give valid consent\n* Referred for coronary angiography or coronary angioplasty\n* Suitable for percutaneous physiological interrogation and PCI when clinically indicated\n\nExclusion Criteria:\n\n* Unable to give valid consent\n* Pregnant or breastfeeding women\n* Unstable coronary artery disease (acute coronary syndrome)\n* Severe multivessel coronary artery disease suitable for coronary artery bypass grafting\n* Severe heart valve disease\n* Severe (NYHA IV) heart failure",{"count":49,"type":19},70,"OBSERVATIONAL","The goal of this observational study is to learn about the factors which determine how well ventricular tachycardia (VT) is tolerated. The main questions it aims to answer are:\n\n1. What impact does coronary artery disease have on the ability for a patient to tolerate VT?\n2. Does treatment of coronary artery disease with stents improve the tolerability of VT?\n\nParticipants who are undergoing a clinically indicated coronary angiogram or coronary angioplasty procedure will have measurements of blood pressure, coronary pressure and coronary flow made during pacing at a range of heart rates.",[53,54,55,25,26],"Ventricular Tachycardia","Coronary Artery Disease","Heart Failure",[53,54,55,25,26,57,58],"Percutaneous Coronary Intervention","Implantable Cardioverter Defibrillator","2026-03-24",{"date":61,"type":31},"2026-03-27",{"date":63,"type":31},"2023-08-01",{"date":65,"type":19},"2026-06-02",{"name":67,"class":68},"Imperial College London","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":50,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":69},"100396335","barts-minoca-registry-100396335","NCT04440761","Barts-MINOCA Registry","Barts Myocardial Infarction With Non-Obstructed Coronary Arteries (MINOCA) Registry","Inclusion Criteria:\n\n* Both male and female patients ≥16 years of age will be included\n* All patients will have a diagnosis MINOCA. Any patient who does not have a clear cause of troponin rise\n\nExclusion Criteria:\n\n* Patients \\\u003C16 years will not be included in this study.","16 Years",{"count":79,"type":19},3000,"5 Years","The last 15 years the introduction of primary angioplasty has radically improved outcomes for acute myocardial infarction (AMI). However, the system wide availability of prompt investigation has revealed an important group of patients where progress has stalled, the diagnosis is unclear and therapeutic approaches are uncertain. Myocardial infarction with non-obstructive coronary arteries (MINOCA) is found in 1 - 13% of all patients with a clinical diagnosis of AMI.\n\nThese patients present a therapeutic predicament since coronary revascularization is not appropriate. Guidelines do not exist for their management - yet the condition is not benign - the 12-month prognosis, although better than obstructive coronary artery disease patients is still guarded with recent data suggesting many questions remain unanswered.",[83,84,26],"Myocardial Infarction","Gender","2025-11-17",{"date":87,"type":31},"2025-11-18",{"date":89,"type":31},"2020-07-01",{"date":91,"type":19},"2026-09-16",{"name":93,"class":68},"Queen Mary University of London",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":102,"minAge":16,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":20,"phases":105,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":69},"100562208","phase-1-study-targeting-myocardial-perfusion-and-symptom-relief-in-women-with-sglt2-inhibitors-strong-100562208","NCT06600178","Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)","Innovative Therapy to Treat Women With Angina With Nonobstructive Coronary Artery Disease (ANOCA) and Coronary Microvascular Disease","STRONG","Inclusion Criteria:\n\n* • Female sex.\n\n  * Age ≥18 years.\n  * Willing and able to provide written informed consent.\n  * Signs and symptoms of suspected ischemia prompted referral for further evaluation by cardiac catheterization or CCTA within two years of consent.\n  * No evidence of obstructive epicardial CAD (stenosis \\\u003C50%) of a major epicardial vessel or an FFR ≤0.80 by invasive catheterization or CCTA. Patients who have not undergone cardiac catheterization of CT angiogram within the last 2 years for chest pain can be scheduled for a screening CT angiogram of the coronary arteries to confirm eligibility.\n  * Diagnosis of CMD defined by CFR \\< 2 by CMR\n  * Never on SGLT2i\n\nExclusion Criteria:\n\n* History of non-ischemic cardiomyopathy LVEF \\\u003C40% or hypertrophic cardiomyopathy.\n* History of congestive heart failure, severe pulmonary disease, liver disease\n* History of acute coronary syndrome (ACS) within previous 30 days\n* Stroke within the last 180 days or intracranial hemorrhage at any time.\n* Severe valvular disease\n* Life expectancy \\\u003C3 years, due to non-cardiovascular comorbidity.\n* Pregnancy or women who are breast-feeding\n* Type 1 diabetes mellitus\n* Symptomatic hypotension or systolic BP \\>95 mmHg on 2 consecutive measurements\n* Active malignancy requiring treatment at the time of visit\n* Severe (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 by CKD-EPI), unstable, or rapidly progressing renal disease at the time of randomization\n* History of recurrent UTI\u002Fbladder\u002Fkidney infections\n* Asthma with ongoing wheezing\n* Known or suspected broncho-constrictive or bronchospastic lung disease (ARDS, emphysema)\n* Greater than first degree heart block\n* Implanted cardiac device\n* Profound sinus bradycardia (heart rate \\\u003C40 beats per minute)\n* Atrial fibrillation or supraventricular arrhythmias at time of imaging\n* Known intolerance of nitrates (other than hypotension)\n* History of reaction to iodinated contrast agents","FEMALE",{"count":104,"type":19},150,[106],"PHASE1","The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are:\n\nAim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with no evidence of epicardial obstructive coronary artery disease.\n\nAim 2: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves angina symptoms and other quality of life measurements associated with the improvement of CFR.\n\nAIM 3: Identify the effect of Sodium-glucose cotransporter 2 inhibition on inflammation pathways and markers of systemic Research will compare Brezavvy to placebo\n\nParticipants will:\n\n* Take study drug or placebo for 12 weeks\n* Stress Cardiac magnetic resonance imaging\n* 12 lead electrocardiograms\n* Complete questionnaires",[109,26,110],"Angina Patients With Non-obstructive Coronary Artery Disease","Coronary Microvascular Dysfunction (CMD)",[112,113,114,115,116,117],"Angina","ANOCA","Non-obstructive Coronary Artery Disease","CMD","Non-Obstructive CAD","Chest Pain in Women","2025-10-27",{"date":120,"type":31},"2025-10-29",{"date":122,"type":31},"2025-06-27",{"date":124,"type":19},"2026-10",{"name":126,"class":68},"University of Virginia",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":145,"locationsCount":69},"100500231","a-study-of-microcirculatory-function-in-type-2-myocardial-infarction-t2mi-100500231","NCT05793567","A Study of Microcirculatory Function in Type 2 Myocardial Infarction (T2MI)","Assessment of Microcirculatory Function in Type 2 Myocardial Infarction","Inclusion Criteria:\n\n* Ability to give informed consent\n* Structurally normal heart (normal LV and RV function, no more than mild valvular heart disease)\n* For controls: atypical chest pain with indication for CMD testing\n* For T2MI: meet criteria for T2MI according to the 4th Universal definition of MI (rise\u002Ffall of troponin with at least 1 value \\>99th centile+ evidence of symptoms or signs of myocardial ischemia)\n\nExclusion Criteria:\n\n* Acute coronary event (evidence of plaque rupture, fissure or dissection on coronary angiogram)\n* Known to have angiographically significant CAD\u002Fpressure wire positive for epicardial CAD\n* Inability to receive heparin products\n* Allergy\u002Fcontraindication to acetylcholine\u002Fadenosine\u002Fnitroglycerine products\n* Prior coronary artery bypass grafting\n* Pregnancy (if sexually active woman of reproductive age, need negative pregnancy test prior to proceeding with coronary angiography - this is standard of care in cath lab)\n* Asthma with prior ICU admission due to bronchospasm\u002Fneed for invasive ventilation",{"count":135,"type":19},52,"The purpose of this research is to find out if patients with Type 2 Myocardial Infarction (T2MI) without significant epicardial coronary artery disease (CAD) have a greater chance of having coronary microvascular disease (CMD).",[83,26],"NOT_YET_RECRUITING","2025-08-21",{"date":141,"type":31},"2025-08-28",{"date":143,"type":19},"2026-08",{"date":35,"type":19},{"name":146,"class":68},"Mayo Clinic",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":155,"enrollmentInfo":156,"targetDuration":158,"studyType":50,"phases":4,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":69},"100568048","an-observational-study-of-coronary-microvascular-disease-of-china-100568048","NCT06676137","An Observational Study of Coronary Microvascular Disease of China","China Coronary Microvascular Disease(CCMD) Registry","CCMD","Inclusion Criteria:\n\n1. Angina symptoms\n2. Objective evidence of myocardial ischemia\n3. Coronary angiography was normal,irregular tube wall, or stenosis \\\u003C50%\n\nExclusion Criteria:\n\n1. People under the age of 18\n2. Non-cardiogenic chest pain and other heart conditions such as variant angina, cardiomyopathy, myocarditis or valvular heart disease","85 Years",{"count":157,"type":19},500,"3 Years","Non-obstructive coronary heart disease refers to patients with angina pectoris without significant narrowing of the epicardial vessels. Coronary microvascular disease(CMD) is a kind of non-obstructive coronary heart disease, and its clinical detection rate is increasing, seriously affecting the quality of life of patients, and increasing the risk of cardiovascular adverse events, but its mechanism has not been fully understood. This study will prospectively collect patients who meet the diagnosis of CMD, observe the development and outcome of the disease, and explore its occurrence and development mechanism.",[26],"2025-08-19",{"date":163,"type":31},"2025-08-20",{"date":165,"type":31},"2024-11-11",{"date":167,"type":19},"2029-10-10",{"name":169,"class":68},"Henan Institute of Cardiovascular Epidemiology",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":69},"100496354","a-clinical-study-of-fundus-octa-for-the-identification-of-cmd-100496354","NCT05743140","A Clinical Study of Fundus OCTA for the Identification of CMD","A Clinical Study of Fundus Optical Coherence Tomography Angiography for the Identification of Coronary Microvascular Diseases","Inclusion Criteria:\n\n1. Patients who underwent coronary angiography in the Department of Cardiology, Peking University First Hospital;\n2. Complete baseline clinical information;\n3. Subject who have coronary angiography results, which shows coronary stenosis \\\u003C 50%;\n4. Older than 18 years;\n5. Subjects who have signed informed consent.\n\nExclusion Criteria:\n\n1. Present serious fundus disease\n2. Severe cataract and other ophthalmic diseases, which affect imaging quality;\n3. Target coronary vessels provide collateral circulation for chronic complete occlusive lesions;\n4. The target coronary angiography agent is poorly filled, overlapped, or severely distorted, and cannot fully expose the location of the lesion;\n5. Coronary angiography images are of poor quality and cannot be identified;\n6. Active bleeding state;\n7. Severe renal insufficiency, contrast agent allergy, and unable to perform coronary angiography.",{"count":178,"type":19},400,"Coronary microvascular dysfunction (CMD) carries an increased risk of adverse cardiovascular clinical outcomes. The association between fundus microcirculation changes and coronary microcirculation is not well understood. Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) is a new type of optical diagnostic imaging technology for non-invasive detection, which can perform multi-dimensional quantitative assessment of fundus microcirculation. In this study, investigators intend to use the coronary angiography-derived index of microvascular resistance (caIMR) to screen patients with CMD, explore the relationship between relevant parameters based on OCT and OCTA measurements and caIMR, and evaluate the feasibility and clinical value of non-invasive identification of CMD through fundus OCT and OCTA.",[26],[182,183,184,185,186],"coronary microvascular disease","CaIMR","OCT","OCTA","Fundus microcirculation","2025-08-07",{"date":189,"type":31},"2025-08-12",{"date":191,"type":31},"2023-03-01",{"date":193,"type":19},"2026-01-01",{"name":195,"class":68},"Peking University First Hospital",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":20,"phases":206,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":69},"100585377","phase-4-clinical-evaluation-of-aromatic-wentong-in-the-treatment-of-coronary-microvascular-disease-100585377","NCT06901570","Clinical Evaluation of Aromatic Wentong in the Treatment of Coronary Microvascular Disease","Clinical Assessment of Aromatic Wentong for Coronary Microvascular Disease Management","Inclusion Criteria:\n\n* Aged between 18 and 80 years, regardless of gender.\n* Clinical symptoms of myocardial ischemia.\n* Objective evidence of myocardial ischemia, including:\n\n  1. ECG changes during chest pain episodes,\n  2. Stress test-induced chest pain symptoms and\u002For abnormal myocardial blood flow and\u002For abnormal cardiac wall motion with ischemic ECG changes.\n* Coronary angiography (CAG) showing \\>50% reduction in the diameter of the epicardial coronary artery.\n* QFR \\> 0.80 and AMR \\> 2.5 mmHg·s\u002Fcm.\n* Discontinuation of all Chinese medicine interventions for at least two weeks prior to enrollment.\n* Provision of informed consent and a signed informed consent form.\n\nExclusion Criteria:\n\n* Significant liver or kidney dysfunction, defined as ALT, AST, or blood creatinine levels \\>3 times the upper limit of normal.\n* Severe cardiac conditions, including heart failure, myocarditis, cardiomyopathy, acute pericarditis, structural heart disease.\n* Severe systemic diseases, such as severe mental illness, hematopoietic system disorders, or malignant tumors.\n* Suspected or confirmed allergy to the trial drug.\n* Individuals deemed by researchers to be unsuitable for participation in the clinical trial.\n* Women who are pregnant, planning to become pregnant, or currently lactating.","80 Years",{"count":205,"type":19},528,[207],"PHASE4","Coronary Microvascular Disease (CMD) is a condition where patients experience chest pain (angina) even though their coronary arteries appear normal on angiography. It is common among people with coronary heart disease, especially those with chest pain as their main symptom. Unfortunately, there are no effective treatments available for these patients, and symptoms like chest tightness and persistent pain greatly affect their quality of life.\n\nTraditional Chinese Medicine (TCM) suggests that the root cause of microvascular disease is blocked collateral blood vessels. Aromatic Wentong, a TCM approach, aims to improve blood flow and relieve blockages. Kuangxiong Aerosol is a Chinese patent medicine developed based on the principles of Aromatic Wentong.\n\nThis study is a multicenter, randomized, double-blind, placebo-controlled trial involving 528 patients with chest pain and suspected CMD. Participants are recruited from several hospitals, including China-Japan Friendship Hospital, Fuwai Hospital, and Xiyuan Hospital. Patients are randomly divided into two groups:\n\nThe intervention group receives standard guideline-recommended treatment plus Kuangxiong Aerosol.\n\nThe control group receives standard treatment plus a placebo version of Kuangxiong Aerosol.\n\nThe treatment lasts for 8 weeks.",[26],"2025-04-09",{"date":212,"type":31},"2025-04-11",{"date":214,"type":19},"2025-04",{"date":216,"type":19},"2028-07",{"name":218,"class":68},"China-Japan Friendship Hospital",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":15,"minAge":227,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":20,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":242},"100556802","impact-of-exercise-training-on-ischemia-with-non-obstructive-coronary-arteries-inoca-the-exinoca-study-100556802","NCT06529848","Impact of Exercise Training on Ischemia With Non-Obstructive Coronary Arteries (INOCA): The ExINOCA Study","Ischemia With No Obstruction of Coronary Arteries: Underlying Mechanisms and the Impact of Exercise Training (EXINOCA)","ExINOCA","Inclusion Criteria:\n\n* Coronary microvascular dysfunction, defined as myocardial bloodflow reserve (MBFR) \\\u003C 2.5 or hyperemic myocar-dial blood flow (hMBF)\\\u003C2.3 ml\u002Fg\u002Fmin using \\[15O\\]H2O-PET\n* No obstructive coronary artery disease\n\nExclusion Criteria:\n\n* Females of childbearing potential (defined as a premeno-pausal female capable of becoming pregnant). The female patient must either be postmenopausal, defined as amen-orrhea for at least 1 year, or surgically sterile\n* Heart failure, defined as left ventricular ejection fraction of less than 40%\n* Uncontrolled hypertension defined as blood pressure above target 140\u002F90 for all\n* Co-morbidity resulting in \\\u003C1 year expected survival\n* Considered by the investigator, for any reason, to be an un-suitable candidate for the study.\n* Unable or unwilling to exercise, e.g. due to arthritis or in-jury\\*\n* Already are regularly physically active and\u002For have a maxi-mal oxygen uptake \\>45 ml\u002Fkg\u002Fmin","50 Years",{"count":229,"type":19},100,[22],"The purpose of the study is to identify causes of chest pain in patients experiencing chest pain with no signs of narrowing of the coronary arteries of the heart, and to investigate whether physical exercise can improve coronary microvascular function.\n\nHypotheses:\n\nThe first hypothesis is that in INOCA, with reduced function of microvasculature of the heart, this reduced function also occurs in other organs of the body.\n\nThe second hypothesis is that regular physical activity (aerobic exercise training) can improve coronary microvascular function, reduce symptoms, and that there is a parallel improvement in vascular function in other organs of the body.",[26,115],"2025-02-20",{"date":235,"type":31},"2025-02-21",{"date":237,"type":31},"2024-11-01",{"date":239,"type":19},"2028-05-15",{"name":241,"class":68},"Bispebjerg Hospital",2,{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":15,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":20,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":39},"100569836","phase-4-qishenyiqi-dripping-pill-for-coronary-microvascular-disease-100569836","NCT06699420","Qishenyiqi Dripping Pill for Coronary Microvascular Disease","The Efficacy and Safety of Qishenyiqi Dripping Pill in Patients With Coronary Microvascular Disease","CMVD","Inclusion Criteria:\n\n* Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks;\n* Coronary normal or stenosis \\\u003C 20%;\n* Ischemic depression in ST segment during resting or exercise;\n* Blood flow reserve (CFR) of the anterior descending coronary artery \\\u003C 2.0;\n* Subjects or their guardians agreed to participate in this study.\n\nExclusion Criteria:\n\n* Previous myocardial infarction or PCI or CABG treatment;\n* A history of heart failure;\n* Severe arrhythmia;\n* Refractory hypertension or hypertension accompanied by left ventricular wall thickness \\> 12 mm;\n* Familial hypercholesterolemia;\n* Takayasu arteritis, Kawasaki disease or coronary artery malformation;\n* Pregnant or nursing, or having the intention to give birth within one year;\n* Hepatic or renal dysfunction;\n* Allergic to contrast agents or traditional Chinese medicines;\n* Patients who participated in clinical research of other drugs within 3 months before being selected.","40 Years","75 Years",{"count":254,"type":19},162,[207],"To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.",[26],"2024-11-20",{"date":260,"type":31},"2024-11-21",{"date":262,"type":31},"2023-11-08",{"date":264,"type":19},"2026-06-30",{"name":266,"class":68},"Qilu Hospital of Shandong University",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":275,"enrollmentInfo":276,"targetDuration":278,"studyType":50,"phases":4,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":69},"100525719","multicenter-registry-on-microvascular-dysfunction---searching-a-new-ach-spasm-definition-100525719","NCT06125392","Multicenter Registry on Microvascular Dysfunction - Searching a New Ach Spasm Definition","A Multicenter RegIstry on the Diagnosis of Patients with Chronic Angina and No Angiographic CoRonary Artery Stenosis (international Retrospective Collection of Anonymized Patient Data) - Searching a New Ach Spasm Definition","MICRO-SNAPE","Inclusion Criteria:\n\n* Patients who underwent combined measurements of coronary pressure and flow in at least 1 native coronary artery in response to endothelium dependent and independent vasodilators.\n\nExclusion Criteria:\n\n* Hemodynamic instability\n* Age \\\u003C18 years","90 Years",{"count":277,"type":19},1000,"1 Year","The MICRO-SNAPE registry will collect data from patients undergoing investigation of microvascular dysfunction and coronary spasm in Europe and North America.",[26,281],"Coronary Vasospasm","2024-10-30",{"date":237,"type":31},{"date":285,"type":31},"2023-09-30",{"date":287,"type":19},"2028-08-31",{"name":289,"class":68},"Johannes Gutenberg University Mainz",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":20,"phases":299,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":69},"100562029","insulin-resistance-and-coronary-microvascular-dysfunction-in-patients-with-myocardial-ischemia-and-non-obstructive-coronary-artery-disease-100562029","NCT06597851","Insulin Resistance and Coronary Microvascular Dysfunction in Patients with Myocardial Ischemia and Non-obstructive Coronary Artery Disease","IRIN","Inclusion Criteria:\n\n* Aged over 18 years.\n* Cardiac chest pain with evidence of myocardial ischemia at noninvasive myocardial stress imaging and clinical indication to diagnostic coronary angiography\n* Willing and able to give informed consent for participation in the study\n\nExclusion Criteria:\n\n* Obstructive CAD (defined as more than 70% luminal stenosis and\u002For FFR ≤0.80 in 1 or more epicardial vessels).\n* History of previous myocardial infarction, percutaneous revascularization or coronary-aortic bypass graft (CABG) surgery.\n* Diagnosis of type II diabetes.\n* BMI ≥ 35 kg\u002Fm2.\n* Stage IV and V of chronic kidney disease (eGFR ≤ 30 ml\u002Fmin, estimated through CKD - EPI Creatinine Equation).\n* Allergy or other contraindication to iodinated contrast and\u002For gadolinium and\u002For adenosine.\n* Chronic resting O2 saturation ≤ 85%.\n* Pregnancy or suspected pregnancy.",{"count":298,"type":19},40,[22],"The goal of this prospective study is to assess the correlation between coronary microvascular disfunction and insulin resistance in patients with INOCA.\n\nPatients with ANOCA and without diabetes will undergo invasive coronary microvascular assessment through coronary angiography and insulin resistance assessment through hyperinsulinemic-euglycemic clamp test.\n\nPatients enrolled in the study will be followed for a period of 2 years to monitor their clinical status.",[25,26,302],"Insulin Resistance",[25,26,302,304,113,115,305],"INOCA","hyperinsulinemic-euglycemic clamp test","2024-09-12",{"date":308,"type":31},"2024-09-19",{"date":310,"type":31},"2024-06-24",{"date":264,"type":19},{"name":313,"class":68},"Azienda Ospedaliera Universitaria Integrata Verona",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":20,"phases":323,"briefSummary":324,"conditions":325,"keywords":326,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":69},"100453007","personalized-medicine-using-coronary-microvascular-function-measured-in-patient-with-percutaneous-coronary-intervention-in-angina-100453007","NCT05178914","Personalized Medicine Using Coronary Microvascular Function Measured in Patient With Percutaneous Coronary Intervention in Angina","DECISIONING","Inclusion Criteria:\n\n* Patient over 18 years\n* Symptomatology of angina pectoris\n* Receiving invasive coronary angiography\n* FFR and microcirculatory resistance index (MRI) measurement for at least one epicardial lesion ≥ 50% :\n* For lesions with FFR ≤ 0.8, revascularization with the XIENCE Sierra stent and its evolutions will be performed. Optimization of this epicardial revascularization will be evidenced by a post-PCI FFR \\> 0.8 on all major trunks and if an FFR measurement is not performed, absence of 50% or greater stenosis on two orthogonal views by quantitative coronary angiography \\[QCA\\] at the revascularization site.\n* For lesions with FFR \\> 0.8 revascularization will not be performed\n* Written informed consent\n\nExclusion Criteria:\n\n* A non-coronary indication for coronary angiography, e.g. valve disease, hypertrophic obstructive cardiomyopathy.\n* Severe renal dysfunction (GFR \\\u003C 30 ml\u002Fmin)\n* Contraindications for adenosine: asthma, Second or third degree AV block without pacemaker or sick sinus syndrome, Systolic blood pressure less than 90 mm Hg, Recent use of dipyridamole or drugs containing dipyridamole, Methyl xanthenes such as caffeine aminophylline or theobromine block the effect of adenosine and should be stored at least 12 hours before testing, Known hypersensitivity to adenosine.\n* Pregnant women, parturients and breastfeeding mothers\n* Persons of full age who are subject to a legal protection measure or who are unable to express their consent\n* Patient in a period of exclusion from another study\n* Patient under administrative or judicial supervision",{"count":322,"type":19},280,[22],"The evidence demonstrating the importance of coronary microcirculation in the management of patients with coronary artery disease is growing. For example, in recent years, a number of studies have demonstrated that the presence of coronary microvascular disease (CMVD) contributes to increased cardiovascular morbidity and mortality independent of the extent and severity of coronary epicardial disease. The index of microcirculatory resistance (IMR) is an invasive index proposed for the diagnosis of CMVD. The ability of IMR to motivate therapeutic changes in order to subsequently reduce symptoms and improves the quality of life of our patients with stable coronary artery disease (CAD) was recently demonstrated. The prognostic value of IMR has also been shown in stable CAD with PCI. Thus, after optimal epicardial evaluation and if necessary revascularization according to FFR, IMR could represent a tool for personalized medicine adapted to the presence of severe CMVD.\n\nThe aim of the study is to demonstrate a positive effect of personalized medicine on angina in patients with epicardial coronary network lesion assessment by FFR and with significant CMVD assessed by IMR.",[26],[327],"index of microcirculatory resistance","2024-06-21",{"date":310,"type":31},{"date":331,"type":31},"2022-03-31",{"date":333,"type":19},"2026-03",{"name":335,"class":68},"University Hospital, Grenoble",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":155,"enrollmentInfo":344,"targetDuration":4,"studyType":20,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":69},"100409051","cosima-coronary-sinus-reducer-for-the-treatment-of-refractory-microvascular-angina-100409051","NCT04606459","COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina","A Multicentric Randomized Open Label Controlled Superiority Trial to Evaluate the Effectiveness of a Therapy With a Coronary Sinus Reducer as Compared to Guideline-directed Medical Therapy in Patients With Refractory Microvascular Angina","COSIMA","Inclusion Criteria:\n\n* Age ≥ 18 and ≤85 years\n* Chronic coronary syndrome (including patients with anginal equivalents) refractory angina CCS class III-IV despite guideline-directed medical therapy\n* Evidence of reversible ischemia on non-invasive testing\n* Evidence of microvascular disease as diagnosed invasively by at least one of the following:\n\n  1. index of microvascular resistances (IMR) \\>25 and\u002For\n  2. coronary flow reserve (CFR) \\\u003C2.0) with fractional flow reserve (FFR)\\>0.8.\n* Willingness to participate and ability to understand, read and sign the informed consent document before enrollment in the trial.\n\nExclusion Criteria:\n\nSubjects presenting at least one of the following criteria will not be enrolled in the trial\n\n* Recent (within 3 months) acute coronary syndrome\n* Recent (within 6 months) revascularization by percutaneous coronary intervention (PCI, stent) or coronary artery by-pass surgery (CABG)\n* Recent (within 30 days) unsuccessful PCI\n* Decompensated congestive heart failure (CHF) or hospitalization due to CHF during the last 3 months\n* Left ventricular ejection fraction of \\\u003C30%\n* Mean right atrial pressure \\>15mmHg\n* Anomalous or abnormal CS anatomy (e.g., tortuosity, aberrant branch, persistent left superior vena cava \\[SVC\\]) as demonstrated by angiogram\n* CS diameter at the site of planned Reducer implantation greater than 13mm or less than 9.5mm as measured by angiogram\n* Severe chronic obstructive pulmonary disease (COPD) indicated by a forced expiratory volume in one second that is less than 55 percent of the predicted value\n* Severe valvular heart disease\n* A pacemaker electrode in the coronary sinus\n* Tricuspid valve replacement or repair\n* Chronic renal failure (serum creatinine \\>2mg\u002FdL), and\u002For on chronic hemodialysis\n* Moribund, or with comorbidities limiting life expectancy to less than one year\n* Known severe reaction to required procedural medications\n* Known allergy to stainless steel or nickel\n* Need for Magnetic Resonance Imaging (MRI) within 8 weeks after reducer implantation\n* Contraindication to dual antiplatelet therapy\n* Female of childbearing potential (last menstruation within the last 12 months or who did not undergo tubal ligation, ovariectomy or hysterectomy)",{"count":345,"type":19},144,[22],"Patients with refractory microvascular angina fulfilling the predefined inclusion and exclusion criteria will be enrolled in this randomized trial. The primary objective is to investigate whether the proportion of patients reporting an improvement in Canadian Cardiovascular Society (CCS) angina class (≥2 classes) is different at six months after implantation of a Coronary Sinus Reducer followed by optimal medical therapy (OMT) compared to OMT alone.",[26,349],"Refractory Angina","2023-09-26",{"date":352,"type":31},"2023-09-28",{"date":354,"type":31},"2021-04-01",{"date":356,"type":19},"2029-10-20",{"name":289,"class":68}]